From: Potentiation of in vitro and in vivoantitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells
Treatment group
Percentage of cells
Live cells
Annexin +ve
Annexin + PI
PI +ve
Control
90.5
3
4
2.3
Doxorubicin ( 100 nM)
60
30.4
8.6
1
P276-00 (1200 nM)
53
38.5
8.2
0.3
Doxorubicin> P276-00
14.1
50.2
34.3
2